Eosinophilic granulomatosis with polyangiitis (EGPA) is one of the rarest forms of vasculitis with primary manifestations of moderate-to-severe asthma and peripheral eosinophilia. Increases in interleukin (IL)-5, a principal eosinophil-mobilizing cytokine, result in eosinophilic inflammation and tissue damage. Combined effects of vascular inflammation and eosinophil infiltration of tissues result in cumulative end-organ damage leading to significant patient morbidity. Pharmacologic neutralization of IL-5 decreases eosinophil counts and can lead to disease remission. Lack of disease awareness and overlap of symptoms with other common conditions often results in delayed recognition and treatment of EGPA.
During this CMEO Snack, Drs. Wechsler and Akuthota will use 3-D models to discuss the pathophysiology and clinical course of EGPA, including eosinophilic manifestations of the disease and the effect of anti-IL-5 therapy on eosinophil activity in EGPA.
Evaluate the pathophysiology and clinical course of EGPA.
This educational activity is supported by an educational grant from GSK.
Physicians, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists specializing in rheumatology, allergy/immunology, pulmonology, nephrologist, internal medicine, and primary care medicine.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Wechsler reports the following financial relationships:
Advisory Board/Consultant: Amgen Inc.; AstraZeneca; Avalo Therapeutics, Inc.; Boehringer Ingelheim; Cerecor Inc.; Cohero Health, Inc.; CytoReason LTD; Eli Lilly and Company; Equillium Bio; GSK; Incyte; Kinaset Therapeutics; Novartis Pharmaceuticals Corporation; Om Pharma; Phylaxis Bioscience, LLC; PULMATRiX, Inc.; RAPT Therapeutics; Regeneron Pharmaceuticals Inc.; Restorbio; Roche/Genentech, Inc.; Sanofi/Genzyme.; Sentien Biotechnologies, Inc.; Sound Biologics; Tetherex Pharmaceuticals; Teva Pharmaceuticals USA, Inc.; and Upstream Bio
Research Support: Amgen Inc.; AstraZeneca; Avalo Therapeutics, Inc.; GSK; Regeneron Pharmaceuticals Inc.; and Sanofi/Genzyme
Speakers Bureau: AstraZeneca; GSK; Regeneron Pharmaceuticals Inc.; and Sanofi
Dr. Akuthota reports the following financial relationships:
Advisory Board: AstraZeneca and GSK
Consultant: AstraZeneca; GSK; and Sanofi
Research Support: AstraZeneca; GSK; Regeneron Pharmaceuticals Inc.; and Sanofi
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).